Northland Securities reiterated their buy rating on shares of ImmuPharma (LON:IMM) in a research report report published on Wednesday morning. They currently have a GBX 181 ($2.45) target price on the stock.

Separately, FinnCap restated a buy rating and set a GBX 237 ($3.21) price target on shares of ImmuPharma in a research note on Thursday, December 21st.

ImmuPharma (LON IMM) opened at GBX 135.50 ($1.84) on Wednesday. The firm has a market cap of $180.24 and a PE ratio of -3,387.50. ImmuPharma has a 52 week low of GBX 44 ($0.60) and a 52 week high of GBX 193.74 ($2.63).

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at

ImmuPharma Company Profile

ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents.

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with's FREE daily email newsletter.